Gynecological Drugs Market - Global Industry Analysis

Name: Gynecological Drugs Market by Therapeutics (Hormonal Therapy and Non-Hormonal Therapy), by Indication (Gynecology Cancers, Endometriosis, Female Infertility, Menopausal Disorder, Gynecology Infections, Polycystic Ovary Syndrome, Contraception (Birth Control), and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025
Brand: Zion Market Research
SKU: ZMR-3926
Price: 4199.00 USD
Availability: InStock
Rating: 4.4 (89 reviews)

Gynecological Drugs Market by Therapeutics (Hormonal Therapy and Non-Hormonal Therapy), by Indication (Gynecology Cancers, Endometriosis, Female Infertility, Menopausal Disorder, Gynecology Infections, Polycystic Ovary Syndrome, Contraception (Birth Control), and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 18-Mar-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3926 Status : Published

Global gynecological drugs market expected to generate around USD 11,429 million by 2025, at a CAGR of around 8.2% between 2019 and 2025. The treatment of gynecological ailments is purely drug-dependent. In recent times, the gynecological pharmacology field has bloomed like never before.

Request For Customization Request Free Brochure Request Free Sample Buy Now

Description

The report covers a forecast and an analysis of the gynecological drugs market on a global and regional level. The study provides historical data for 2016, 2017, and 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the gynecological drugs market along with the impact they have on the demand over the estimated period. Additionally, the report includes the study of opportunities available in the gynecological drugs market on a global level.

In order to give the users of this report a comprehensive view of the gynecological drugs market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Gynecological Drugs Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, R&D, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.

The study provides a decisive view of the gynecological drugs market by segmenting the market based on therapeutics, indication, distribution channel, and region. All the segments have been analyzed based on present and future trends in the market that is estimated from 2019 to 2025. Based on therapeutics, the market is segmented into hormonal therapy and non-hormonal therapy. Based on the indication, the market is segmented into gynecology infections, gynecology cancers, endometriosis, polycystic ovary syndrome, female infertility, menopausal disorder, contraception (birth control), and others. Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further segmentation into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil.

Some key players of the gynecological drugs market are Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Pfizer, Inc., Amgen Inc., AstraZeneca, Allergan, and Bayer AG, among others.

The report segments the global gynecological drugs market into:

Global Gynecological Drugs Market: Therapeutics Analysis

Hormonal therapy
Non-Hormonal therapy

Global Gynecological Drugs Market: Indication Type Analysis

Gynecology Cancers
Endometriosis
Female Infertility
Menopausal Disorder
Gynecology Infections
Polycystic Ovary Syndrome
Contraception (Birth Control)
Others

Global Gynecological Drugs Market: Distribution Channel Analysis

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Gynecological Drugs Market: Regional Analysis

North America
- The U.S.
Europe
- UK
- France
- Germany
Asia Pacific
- China
- Japan
- India
Latin America
- Brazil
Middle East and Africa

Table Of Content

Chapter 1. Introduction
- 1.1. Report description and scope
- 1.2. Research scope
- 1.3. Research methodology
  - 1.3.1. Market research process
  - 1.3.2. Market research methodology
Chapter 2. Executive Summary
- 2.1. Global Gynecological Drugs Market, 2016-2025 (USD Million)
- 2.2. Global Gynecological Drugs Market: Snapshot
Chapter 3. Gynecological Drugs Market - Market Dynamics
- 3.1. Introduction
- 3.2. Market drivers
  - 3.2.1. Global Gynecological Drugs market drivers: Impact analysis
  - 3.2.2. Rising healthcare expenditure
  - 3.2.3. Changing lifestyle of females across the globe
- 3.3. Market Restraints
  - 3.3.1. High cost
  - 3.3.2. Lack of skilled professionals
- 3.4. Opportunities
  - 3.4.1. Technological advancement
  - 3.4.2. Increase in Research and development activities
- 3.5. Porter's Five Forces Analysis
- 3.6. Market attractiveness analysis
  - 3.6.1. Market attractiveness analysis, by Therapeutics
  - 3.6.2. Market attractiveness analysis, by Indication
  - 3.6.3. Market attractiveness analysis, by Distribution Channel
  - 3.6.4. Market attractiveness analysis, by Region
Chapter 4. Global Gynecological Drugs Market - Competitive Landscape
- 4.1. Company Market Share Analysis
  - 4.1.1. Global Gynecological Drugs Market: company market share, 2016
- 4.2. Strategic Development
  - 4.2.1. Acquisitions & Mergers
  - 4.2.2. New Launch
  - 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
  - 4.2.4. R&D
  - 4.2.5. Regional Expansion
- 4.3. Price Trend Analysis
- 4.4. Therapeutics Portfolio
Chapter 5. Global Gynecological Drugs Market - Therapeutics Type Analysis
- 5.1. Global Gynecological Drugs Market: Therapeutics overview
  - 5.1.1. Global Gynecological Drugs market revenue share, by Therapeutics, 2018 and 2025
- 5.2. Hormonal therapy
  - 5.2.1. Global Hormonal therapy Market, 2016-2025 (USD Million)
- 5.3. Non-hormonal therapy
  - 5.3.1. Global Non-hormonal therapy Market, 2016-2025 (USD Million)
Chapter 6. Global Gynecological Drugs Market - Indication Analysis
- 6.1. Global Gynecological Drugs: Indication overview
  - 6.1.1. Global Gynecological Drugs Market revenue share, by Indication, 2018 and 2025
- 6.2. Gynecology cancers
  - 6.2.1. Global Gynecology Cancers Market, 2016-2025 (USD Million)
- 6.3. Endometriosis
  - 6.3.1. Global Endometriosis Market, 2016-2025 (USD Million)
- 6.4. Female infertility
  - 6.4.1. Global Female infertility Market, 2016-2025 (USD Million)
- 6.5. Menopausal disorder
  - 6.5.1. Global Menopausal disorder Market, 2016-2025 (USD Million)
- 6.6. Gynecology infections
  - 6.6.1. Global Gynecology infections Market, 2016-2025 (USD Million)
- 6.7. Polycystic ovary syndrome
  - 6.7.1. Global Polycystic ovary syndrome Market, 2016-2025 (USD Million)
- 6.8. Contraception (birth control)
  - 6.8.1. Global Contraception (birth control) Market, 2016-2025 (USD Million)
- 6.9. Others
  - 6.9.1. Global Others Market, 2016-2025 (USD Million)
Chapter 7. Global Gynecological Drugs Market - Distribution Channel Analysis
- 7.1. Global Gynecological Drugs Market: Distribution Channel overview
  - 7.1.1. Global Gynecological Drugs Market revenue share, by Distribution Channel, 2018 and 2025
- 7.2. Hospital Pharmacies
  - 7.2.1. Global Hospital Pharmacies Market, 2016-2025 (USD Million)
- 7.3. Retail Pharmacies
  - 7.3.1. Global Retail Pharmacies Market, 2016-2025 (USD Million)
- 7.4. Online Pharmacies
  - 7.4.1. Global Online Pharmacies Market, 2016-2025 (USD Million)
Chapter 8. Global Gynecological Drugs Market - Regional Analysis
- 8.1. Global Gynecological Drugs Market: Regional overview
  - 8.1.1. Global Gynecological Drugs Market revenue share, by region, 2018 and 2025
- 8.2. North America
  - 8.2.1. North America Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
  - 8.2.2. North America Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
  - 8.2.3. North America Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.2.4. The U.S.
    - 8.2.4.1. The U.S. Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.2.4.2. The U.S. Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.2.4.3. The U.S. Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.2.5. Rest of North America
    - 8.2.5.1. Rest of North America Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.2.5.2. Rest of North America Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.2.5.3. Rest of North America Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
- 8.3. Europe
  - 8.3.1. Europe Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
  - 8.3.2. Europe Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
  - 8.3.3. Europe Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.3.4. Germany
    - 8.3.4.1. Germany Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.3.4.2. Germany Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.3.4.3. Germany Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.3.5. France
    - 8.3.5.1. France Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.3.5.2. France Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.3.5.3. France Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.3.6. UK
    - 8.3.6.1. UK Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.3.6.2. UK Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.3.6.3. UK Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.3.7. Rest of Europe
    - 8.3.7.1. Rest of Europe Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.3.7.2. Rest of Europe Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.3.7.3. Rest of Europe Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
- 8.4. Asia Pacific
  - 8.4.1. Asia Pacific Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
  - 8.4.2. Asia Pacific Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
  - 8.4.3. Asia Pacific Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.4.4. China
    - 8.4.4.1. China Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.4.4.2. China Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.4.4.3. China Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.4.5. Japan
    - 8.4.5.1. Japan Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.4.5.2. Japan Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.4.5.3. Japan Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.4.6. India
    - 8.4.6.1. India Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.4.6.2. India Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.4.6.3. India Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.4.7. Rest of Asia Pacific
    - 8.4.7.1. Rest of Asia Pacific Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.4.7.2. Rest of Asia Pacific Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.4.7.3. Rest of Asia Pacific Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
- 8.5. Latin America
  - 8.5.1. Latin America Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
  - 8.5.2. Latin America Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
  - 8.5.3. Latin America Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.5.4. Brazil
    - 8.5.4.1. Brazil Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.5.4.2. Brazil Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.5.4.3. Brazil Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
  - 8.5.5. Rest of Latin America
    - 8.5.5.1. Rest of Latin America Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
    - 8.5.5.2. Rest of Latin America Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
    - 8.5.5.3. Rest of Latin America Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
- 8.6. The Middle East and Africa
  - 8.6.1. The Middle East and Africa Gynecological Drugs market revenue, by Therapeutics, 2016-2025 (USD Million)
  - 8.6.2. The Middle East and Africa Gynecological Drugs market revenue, by Indication, 2016-2025 (USD Million)
  - 8.6.3. The Middle East and Africa Gynecological Drugs market revenue, by Distribution Channel, 2016-2025 (USD Million)
Chapter 9. Company Profile
- 9.1. Eli Lilly and Company
  - 9.1.1. Overview
  - 9.1.2. Financials
  - 9.1.3. Therapeutics portfolio
  - 9.1.4. Business strategy
  - 9.1.5. Recent developments
- 9.2. Pfizer, Inc.
  - 9.2.1. Overview
  - 9.2.2. Financials
  - 9.2.3. Product Type portfolio
  - 9.2.4. Business strategy
  - 9.2.5. Recent developments
- 9.3. Merck & Co., Inc.
  - 9.3.1. Overview
  - 9.3.2. Financials
  - 9.3.3. Product Type portfolio
  - 9.3.4. Business strategy
  - 9.3.5. Recent developments
- 9.4. Amgen Inc.
  - 9.4.1. Overview
  - 9.4.2. Financials
  - 9.4.3. Product Type portfolio
  - 9.4.4. Business strategy
  - 9.4.5. Recent developments
- 9.5. AstraZeneca
  - 9.5.1. Overview
  - 9.5.2. Financials
  - 9.5.3. Product Type portfolio
  - 9.5.4. Business strategy
  - 9.5.5. Recent developments
- 9.6. F. Hoffmann-La Roche Ltd.
  - 9.6.1. Overview
  - 9.6.2. Financials
  - 9.6.3. Product Type portfolio
  - 9.6.4. Business strategy
  - 9.6.5. Recent developments
- 9.7. Allergan
  - 9.7.1. Overview
  - 9.7.2. Financials
  - 9.7.3. Product Type portfolio
  - 9.7.4. Business strategy
  - 9.7.5. Recent developments
- 9.8. Bayer AG
  - 9.8.1. Overview
  - 9.8.2. Financials
  - 9.8.3. Product Type portfolio
  - 9.8.4. Business strategy
  - 9.8.5. Recent developments

Methodology

Free Analysis

The treatment of gynecological ailments is purely drug-dependent. In recent times, the gynecological pharmacology field has bloomed like never before. Furthermore, the availability of the ultraprecise advanced gynecological investigation, direct monitoring facility, and various medical options for the treatment of gynecological ailments is increasing. With the establishment of down and up-regulation policies, the different treatment options, such as hypothalamus and pituitary, have now become a very easy tool for gynecologists to treat hormonal disorders. These gynecological disorders include conditions affecting ovaries, uterus, and their appendages.

There are various factors expected to support the growth of the global gynecological drugs market in the future, such as the increasing prevalence of gynecological diseases. Changing lifestyle of females across the globe has eventually put them at a higher risk of suffering from various types of gynecological disorders, which, in turn, is fuelling the global gynecological drugs market. The awareness about one’s well-being and health has increased, which has led to the rise for better gynecological treatments and the manufacturers have innovated newer drugs for treating gynecological disorders with fewer side-effects and better efficacy. These are also projected to fuel this global market.

Global Gynecological Drugs Market

The gynecological drugs market is segmented into the distribution channel, therapeutics, and indication. Based on therapeutics, the market is segmented into hormonal therapy and non-hormonal therapy. Non-hormonal therapy is expected to hold the major market share over the estimated timeline. Based on the indication, the market is segmented into gynecology infections, gynecology cancers, endometriosis, polycystic ovary syndrome, female infertility, menopausal disorder, contraception (birth control), and others. Polycystic ovary syndrome is expected to grow significantly over the forecast timeline. Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies held the major share of the global market in 2018.

North America is expected to lead the global gynecological drugs market over the forecast timeline, due to the high expenditure on women’s health, substantial research and development activities witnessed in the gynecology domain. Europe is predicted to trail behind North America in terms of growth and be the second largest gynecological drugs market in the years ahead. Asia Pacific is likely to record a high CAGR over the forecast timeframe, owing to the introduction of new and approved gynecological drugs, the presence of strong healthcare infrastructure, increased affordability of the gynecological drugs, and technological advancements.